文献速递神经核医学核素与放射性配体治疗

68Ga-DOTATATE PET/CT 显示侵袭眶内的难治性垂体大腺瘤

68Ga-DOTATATE PET/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit.
PubMed 文献 · Clin Nucl Med · 2021-01-01

本文报告一例60岁男性难治性侵袭性垂体大腺瘤病例,68Ga-DOTATATE PET/CT 显示病灶对该示踪剂高摄取。基于此摄取,曾考虑予以177Lu-DOTATATE 治疗,但最终未实施,提示诊疗一体化在困难病例中的潜在价值。

要点

  • 垂体大腺瘤可表达生长抑素受体,68Ga-DOTATATE PET/CT 可显示其摄取。
  • 该例病灶侵袭眶内且对传统治疗持续难治。
  • 高摄取提示177Lu-DOTATATE 治疗可能成为潜在选择。

核心结论

  • 68Ga-DOTATATE PET/CT 可显示侵袭眶内的难治性垂体大腺瘤的高摄取,并据此提出177Lu-DOTATATE 治疗的可能性。

研究设计与样本

  • 个案报道:一例60岁男性难治性侵袭性垂体大腺瘤患者接受68Ga-DOTATATE PET/CT 检查。

主要发现

  • 68Ga-DOTATATE PET/CT 显示该侵袭性垂体大腺瘤对示踪剂高摄取,病灶在传统治疗后仍持续且难治。
  • 因摄取阳性,曾提供177Lu-DOTATATE 治疗选项,但最终未实际进行。

临床怎么用

  • 对传统治疗难治且侵袭性生长的垂体大腺瘤,可考虑生长抑素受体显像评估摄取。
  • 若68Ga-DOTATATE 摄取明显,可讨论177Lu-DOTATATE 等诊疗一体化治疗的可能性。

局限性

  • 为单一个案报道,未提供治疗实施后的疗效或安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In addition to gastroenteropancreatic neuroendocrine neoplasms, a wide variety of tumors express somatostatin receptors. Somatostatin receptor imaging, heavily utilized in neuroendocrine oncology, may also have utility in the diagnosis of other neoplasms and raises the possibility of potential therapeutic options. We describe the case of a 60-year-old man who underwent 68Ga-DOTATATE PET/CT, demonstrating an avid invasive pituitary macroadenoma. This mass was persistent and refractory despite traditional treatment options. Because of the avidity, 177Lu-DOTATATE therapy was offered, although not ultimately performed, demonstrating a potential treatment for challenging cases utilizing the principles of theranostics.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lybik N, Wale DJ, Wong KK, et al. 68Ga-DOTATATE PET/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit. Clin Nucl Med. 2021. PMID: 33782291. doi:10.1097/RLU.0000000000003589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。